関連する実験動画

Updated: May 5, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

アルツハイマー病の進行を予測する転倒

Audrey A Keleman^1,2,3, Melody Li⁴, Julie K Wisch⁴

¹Program in Occupational Therapy, Washington University School of Medicine, St. Louis, Missouri, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association

|February 7, 2026

要旨

Introduction:

In preclinical Alzheimer's disease (AD), amyloid accumulates in the brain while individuals remain cognitively unimpaired (Clinical Dementia Rating^® [CDR] = 0). Differentiating trajectories of healthy aging and preclinical AD is challenging as both are associated with age-related impairments (e.g., falls).

Methods:

Longitudinal cohort study. We monitored falls for 1 year among 125 CDR 0 older adults and assessed preclinical AD status (amyloid). We continued to evaluate CDR annually (median 10 years). The cohort was grouped: Preclinical AD-Fall-, Preclinical AD-Fall+, Preclinical AD+Fall-, and Preclinical AD+Fall+. Survival analysis examined time to progression to CDR 1 (mild dementia) by group.

Results:

Participants were 74 years (mean) at baseline, 62% female, 96% White. Preclinical AD+Fall+ progressed to CDR 1 most rapidly. Preclinical AD-Fall- progressed least quickly. Preclinical AD+Fall- and Preclinical AD-Fall+ had similar progression rates.

Discussion:

Falls may associate with faster progression of AD dementia, potentially reflecting motor and gait dysfunction intrinsic to disease progression.

キーワード:

アルツハイマー病老化アミロイド認知症転倒

さらに関連する動画

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

関連する概念動画

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...